Short-Term Debt to Equity Ratio: Jupiter Neurosciences Inc (JUNS)
Jupiter Neurosciences Inc (JUNS) is a biotech developer of migraine and dementia treatments utilizing an innovative method for delivering resveratrol to the brain. However, the company faces significant uncertainty due to potential research failures and a shortage of funds. The current metric stands at 0.00. Serving as a valuation tool, this price chart illustrates the financial condition of the firm, which created a unique CNS treatment system with the drug Jotrol.
Comprehensive metric breakdowns and analytics for Jupiter Neurosciences, Inc. (JUNS)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Jupiter Neurosciences Inc|JUNS - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Jupiter Neurosciences Inc|JUNS - Company Aggregate Debts|Debt to Book Capitalization Ratio Jupiter Neurosciences, Inc.|JUNS - Long-Term Liabilities|Company Short-Term Debts Jupiter Neurosciences|Quick Liquidity Indicator jupiterneurosciences.com
- company profitability and valuation multiples indicators:
Comprehensive company analysis:JUNS Jupiter Neurosciences
For Jupiter Neurosciences Inc (JUNS), whose R&D risks and operating losses are already priced in by the market, this indicator determines the degree of liquidity dependence on short-term borrowings relative to equity. By analyzing the chart of the short-term loan-to-equity ratio on GURU.Markets, an investor assesses the coverage of net assets by liabilities under one year, which is critical when awaiting long-term results from clinical trials of innovative molecules.
Competitor analysis for Jupiter Neurosciences Inc
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|DNLI (denalitherapeutics.com) - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio HRMY (Harmony Biosciences Holdings, Inc.)|Short-Term Debt to Capital Biohaven Ltd (BHVN)|Short-Term Debt to Equity Amylyx AMLX|TRVI (Trevi Corp) - Current Liabilities to Equity|Praxis Precision Medicines - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient anavex.com AVXL|CBLL (CeriBell) - Short-Term Debt to Equity Ratio|PRTA: Short-Term Loans to Capital Ratio|ALEC (Alector Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Annexon Biosciences Inc. ANNX|Short-Term Debt to Equity Omeros Corporation (OMER)|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|NMRA - Short-Term Debt to Equity|SCLX (Scilex Holding Company, Inc.) - Short-Term Debt to Capital Ratio|TVGN: Short-Term Debt to Capital|Current Liabilities to Capital Alpha Cognition Inc. (ACOG)|Short-Term Debt to Equity Ratio CGTX|Short-Term Debt to Capital Inhibikase Therapeutics Inc|Short-Term Debt to Equity Cassava (SAVA)|ASRT (assertiotx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Coya Therapeutics COYA|VistaGen Therapeutics, Inc. (VTGN) - Current Liabilities to Capital|OVID - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Acumen Pharmaceuticals Inc. ABOS|CRVO: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Alterity Therapeutics Limited|CLNN (Clene Inc) - Short-Term Debt to Capital|PepGen Corp (PEPG) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital RLMD|ANVS - Current Liabilities to Capital|Short-Term Debt to Equity Grace Therapeutics GRCE|AIFF: Short-Term Debt to Capital Ratio|ANEW Medical, Inc. - Short-Term Debt to Capital|NeuroSense Therapeutics (NRSN) - Short-Term Debt to Equity Ratio|RVPH: Short-Term Debt to Capital|Current Liabilities to Capital MetaVia (MTVA)|Short-Term Debt to Equity NeurAxis, Inc|Helius Medical Technologies Inc. (HSDT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|NEUP (bionomics.com.au) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Debt to Capital Coefficient Athira Pharma Inc (ATHA)|ADXN - Short-Term Debt to Equity|ALZN (Alzamend Neuro, Inc.) - Short-Term Debt to Capital Ratio|CYCN: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Protagenic Therapeutics, Inc.|Short-Term Debt to Equity Pasithea Therapeutics Corp|CRGT (Cortigent Medical) - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio ATXI (Avenue Therapeutics, Inc)|Short-Term Debt to Capital BrainStorm Cell Therapeutics Inc. (BCLI)|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|CHRO: Short-Term Debt to Capital Ratio|ELYM - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Intra-Cellular Therapies ITCI|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio MRNS|NKGN (NKGen Biotech, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Ratio SAGE (Sage Therapeutics)|Short-Term Debt to Capital Synaptogenix Inc. (SNPX)|Short-Term Debt to Equity Trevena, Inc TRVN|Ratio of Short-Term Indebtedness to Capital VIGL|WENA - Short-Term Debt to Equity|Current Liabilities to Capital cerevel.com